The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Proposed updates to AML classification: implications for clinical trials and practice
Robert Hasserjian, MD, Massachusetts General Hospital, Boston, MA, presents proposed updates to the classification of acute myeloid leukemia (AML) from the Classification Advancements Meeting (CAM) and discusses the implications for diagnosis and treatment. Dr Hasserjian recommends that all cases of AML undergo comprehensive genetic testing and be classified according to a defined hierarchy. He discusses key categories, including AML with recurrent genetic abnormalities, AML with mutated TP53, myelodysplasia-related AML defined by mutations or cytogenetic abnormalities, and AML defined by differentiation. This presentation took place at the 8th International Workshop on Acute Leukemias (iwAL) in Cambridge, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
